TREMFYA® Sub-Populations | TREMFYA® (guselkumab) | HCP

TREMFYA® EFFICACY DATA IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
EFFICACY IN SUBPOPULATIONS

TREMFYA® Is Proven Effective in Difficult-to-Treat Scalp Psoriasis: More Than 4 Out of 5 Patients Were Rated as Cleared or Almost Cleared (ss-IGA 0/1) of Scalp Psoriasis at Week 161,2*

VOYAGE 1: ss-IGA 0/1, MAJOR SECONDARY ENDPOINT

Example of scalp psoriasis; not an actual TREMFYA® patient. Image is for illustrative purposes only and is used with permission from Janssen Biotech, Inc.

Based on the results of an analysis of the 101 global sites from VOYAGE 1 (including North American sites [ie, United States and Canada]).

*In a subpopulation of patients with scalp-specific Investigator's Global Assessment (ss-IGA) score ≥2 at baseline, ss-IGA scores were assessed in terms of clinical signs of redness, thickness, and scaliness using a 5-point scale where overall lesions were rated as absence of disease (0), very mild (1), mild (2), moderate (3), or severe (4).

Consistent PASI 90 Response With TREMFYA® at Week 24 Regardless of Body Weight1

POST HOC ANALYSIS: POOLED DATA FROM VOYAGE 1 AND VOYAGE 2—PASI 90 AT WEEK 24 (NORTH AMERICAN ANALYSIS)

No differences in response to TREMFYA® were identified among the following subgroups: age, gender, race, body weight, and previous treatment with systemic or biologic agents.3

TREMFYA® vs Humira® analysis is based on the pooled results of an analysis of 38 North American sites (United States=27, Canada=11) from VOYAGE 1 and 41 North American sites (United States=31, Canada=10) from VOYAGE 2 that used US-licensed Humira®.

References: 1. Data on file. Janssen Biotech, Inc. 2. Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405-417. 3. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.